Wuhan Hvsen Biotechnology Co Ltd (300871) — Cash Flow-to-Debt Ratio
Wuhan Hvsen Biotechnology Co Ltd (300871) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of CN¥59.06 Million could theoretically repay 0% of its total liabilities (CN¥839.94 Million) in one year. Check total reinvestment intensity of Wuhan Hvsen Biotechnology Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wuhan Hvsen Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Wuhan Hvsen Biotechnology Co Ltd across 10 annual periods. Also explore 300871 current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
Year-by-year debt coverage analysis for Wuhan Hvsen Biotechnology Co Ltd. For market capitalisation and broader financial context, see Wuhan Hvsen Biotechnology Co Ltd (300871) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | CN¥238.45 Million | CN¥822.17 Million | ▲ +932.3% |
| 2024 | 0.03x | CN¥43.53 Million | CN¥1.55 Billion | ▼ -55.7% |
| 2023 | 0.06x | CN¥92.92 Million | CN¥1.47 Billion | ▼ -5.1% |
| 2022 | 0.07x | CN¥96.68 Million | CN¥1.45 Billion | ▼ -51.8% |
| 2021 | 0.14x | CN¥155.72 Million | CN¥1.12 Billion | ▲ +7.0% |
| 2020 | 0.13x | CN¥48.35 Million | CN¥373.08 Million | ▼ -66.5% |
| 2019 | 0.39x | CN¥105.24 Million | CN¥271.80 Million | ▲ +160.8% |
| 2018 | 0.15x | CN¥21.10 Million | CN¥142.08 Million | ▼ -77.7% |
| 2017 | 0.67x | CN¥80.56 Million | CN¥121.06 Million | ▲ +12.2% |
| 2016 | 0.59x | CN¥60.00 Million | CN¥101.16 Million | — |